阿德福韦酯联合拉米夫定治疗乙肝肝硬化的临床效果分析

Clinical Effect Analysis of Adefovir Dipivoxil Combined with Lamivudine in Treatment of Hepatitis B Cirrhosis

目的在乙肝肝硬化患者治疗中采用阿德福韦酯联合拉米夫定治疗,分析临床效果。方法随机自我院2017年3月至2018年2月患者资料库中选取56例乙肝肝硬化患者入组,根据数字表法分组,28例实验组患者行阿德福韦酯联合拉米夫定治疗,28例对照组患者行拉米夫定治疗。结果实验组患者治疗1个月时TBLL、ALB、ALT、PTA、HBV DNA水平、HBV DNA转阴率均获得了明显改善,改善程度明显优于对照组患者,差异明显,P<0.05。2组患者治疗前TBLL、ALB、ALT、PTA对比结果不存在统计学差异,P>0.05。结论在乙肝肝硬化患者治疗中采用阿德福韦酯联合拉米夫定治疗,临床效果较为理想。

Objective to analyze clinical effect of adefovir dipivoxil combined with lamivudine in treatment of hepatitis B cirrhosis. Methods choose 56 cases hepatitis B cirrhosis patients in database of our hospital from March 2017 to February 2018 randomly. According to digital table method, 28 cases in experiment group were treated with adefovir dipivoxil combined with lamivudine, and 28 cases in control group with lamivudine. Results TBLL, ALB, ALT, PTA, HBV DNA level and HBV DNA negative rate of experimental group was significantly improved after 1 month of treatment, improvement degree was obviously better than control group, with obvious difference, P0.05. TBLL, ALB, ALT and PTA comparison showed no significant difference between two groups before treatment, P0.05. Conclusion adefovir dipivoxil combined with lamivudine has ideal effect in treatment of hepatitis B cirrhosis.